VIDEO: Positive MARIPOSA data shows potential of amivantamab in EGFR-mutated NSCLC
MADRID — In this video, Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discussed MARIPOSA data on amivantamab in EGFR-mutated advanced lung cancer presented at ESMO Congress.
Primary results from MARIPOSA, a phase 3, global, randomized, controlled trial, showed that amivantamab (Rybrevant, Janssen) plus lazertinib (Leclaza; Yuhan, Janssen) was statistically superior to osimertinib (Tagrisso, AstraZeneca) in patients with EGFR-mutated advanced NSCLC.
In MARIPOSA-2, researchers found that both amivantamab plus chemotherapy and amivantamab plus lazertinib plus chemotherapy improved PFS, objective response rate and intracranial PFS compared with chemotherapy alone in EGFR-mutated advanced NSCLC after progression on osimertinib.
References:
- Cho B, et al. Abstract LBA14. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
- Passaro A, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Read more about